Full Logo - OKYO .jpg
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
December 30, 2022 02:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease...
Full Logo - OKYO .jpg
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
December 22, 2022 02:00 ET | OKYO Pharma LTD
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in...
Full Logo - OKYO .jpg
OKYO to Participate at Biotech Showcase
December 21, 2022 02:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
December 06, 2022 02:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Limited - Change of Auditor
December 01, 2022 02:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Limited – PDMR dealing
November 24, 2022 02:00 ET | OKYO Pharma LTD
LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
November 21, 2022 02:00 ET | OKYO Pharma LTD
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE...
Full Logo - OKYO .jpg
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
November 10, 2022 06:00 ET | OKYO Pharma LTD
Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology...
Full Logo - OKYO .jpg
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
September 08, 2022 09:25 ET | OKYO Pharma LTD
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat...
Full Logo - OKYO .jpg
OKYO Pharma Limited: Result of Annual General Meeting
September 07, 2022 09:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative...